Full details about HCC

Reading File
Finding Sources
Searching PubMed

"hepatocellular carcinoma"[MeSH Terms] AND ("diagnosis" OR "treatment")

Searching Images

hepatocellular carcinoma HCC liver imaging histology

High-magnification light microscopy of a liver neoplasm stained with Hematoxylin and Eosin. The micrograph shows the fibrolamellar pattern, with thick, lamellar bands of dense, eosinophilic collagen (fibrous stroma) separating broad cords of neoplastic hepatocytes. The tumor cells are large and polygonal, with abundant granular eosinophilic cytoplasm and nuclei that are relatively large with prominent nucleoli. Cell borders are distinct and the architectural pattern resembles trabeculae separated by dense fibrous lamellae. The dense fibrosis produces a parallel, scirrhous-like appearance, contrasted with conventional HCC variants that lack diffuse parallel fibrosis. Immunophenotype is not provided in the image. This histology supports fibrolamellar hepatocellular carcinoma (FL-HCC), a hepatocellular carcinoma variant typically arising in noncirrhotic livers and younger patients, and distinguished from the scar-like scirrhous pattern of typical HCC by the combination of abundant cytoplasmic granularity and orderly fibrous bands. Diagnosis has prognostic and therapeutic relevance, as FL-HCC often exhibits distinct biology and prognosis compared with conventional HCC. This image is valuable for pathology education, morphologic differentiation, and search queries focused on FL-HCC, HCC scirrhous pattern, hepatocellular tumors with fibrous stroma, and high-detail liver histology. Correlate with clinical history, correlate with imaging findings, and consider immunohistochemistry if requested for confirmation.

High-magnification light microscopy of a liver neoplasm stained with Hematoxylin and Eosin. The micrograph shows the fibrolamellar pattern, with thick, lamellar bands of dense, eosinophilic collagen (fibrous stroma) separating broad cords of neoplastic hepatocytes. The tumor cells are large and polygonal, with abundant granular eosinophilic cytoplasm and nuclei that are relatively large with prominent nucleoli. Cell borders are distinct and the architectural pattern resembles trabeculae separated by dense fibrous lamellae. The dense fibrosis produces a parallel, scirrhous-like appearance, contrasted with conventional HCC variants that lack diffuse parallel fibrosis. Immunophenotype is not provided in the image. This histology supports fibrolamellar hepatocellular carcinoma (FL-HCC), a hepatocellular carcinoma variant typically arising in noncirrhotic livers and younger patients, and distinguished from the scar-like scirrhous pattern of typical HCC by the combination of abundant cytoplasmic granularity and orderly fibrous bands. Diagnosis has prognostic and therapeutic relevance, as FL-HCC often exhibits distinct biology and prognosis compared with conventional HCC. This image is valuable for pathology education, morphologic differentiation, and search queries focused on FL-HCC, HCC scirrhous pattern, hepatocellular tumors with fibrous stroma, and high-detail liver histology. Correlate with clinical history, correlate with imaging findings, and consider immunohistochemistry if requested for confirmation.

Histopathology: Light microscopy of a liver tumor with a solid growth pattern consistent with hepatocellular carcinoma (HCC). The specimen is a hepatic parenchymal tissue section stained with hematoxylin and eosin (H&E). Tumor cells form uniform, monomorphic sheets with evenly distributed nuclei, conspicuous nucleoli, and abundant eosinophilic cytoplasm. Bile production is prominent within tumor cells, and portal tracts are absent from the neoplasm, a feature typical of HCC. In this pattern, trabecular arrangements are compressed rather than endothelial cell-wrapped, requiring immunomarkers to highlight residual vascular architecture when necessary. The background liver shows preserved or cirrhotic changes depending on the sample. The differential diagnosis includes conventional trabecular HCC, fibrolamellar variant, and metastatic hepatobiliary tumors; however, the distinct solid sheets and lack of portal triads favor primary liver origin. Clinically, this histology supports a diagnosis of hepatocellular carcinoma, informs prognosis, and guides management, including surgical resection or locoregional therapies and systemic considerations. This image is suitable for pathology education, diagnostic correlation with imaging (CT/MRI), and research on HCC subtypes. Immunophenotype clues (if stained) include HepPar1 and glypican-3 positivity supporting hepatocellular origin; CD34 highlights sinusoidal capillarization in many HCCs; CK19 is typically negative or focally positive in certain variants; clinical correlation remains essential. Interpretation.

Histopathology: Light microscopy of a liver tumor with a solid growth pattern consistent with hepatocellular carcinoma (HCC). The specimen is a hepatic parenchymal tissue section stained with hematoxylin and eosin (H&E). Tumor cells form uniform, monomorphic sheets with evenly distributed nuclei, conspicuous nucleoli, and abundant eosinophilic cytoplasm. Bile production is prominent within tumor cells, and portal tracts are absent from the neoplasm, a feature typical of HCC. In this pattern, trabecular arrangements are compressed rather than endothelial cell-wrapped, requiring immunomarkers to highlight residual vascular architecture when necessary. The background liver shows preserved or cirrhotic changes depending on the sample. The differential diagnosis includes conventional trabecular HCC, fibrolamellar variant, and metastatic hepatobiliary tumors; however, the distinct solid sheets and lack of portal triads favor primary liver origin. Clinically, this histology supports a diagnosis of hepatocellular carcinoma, informs prognosis, and guides management, including surgical resection or locoregional therapies and systemic considerations. This image is suitable for pathology education, diagnostic correlation with imaging (CT/MRI), and research on HCC subtypes. Immunophenotype clues (if stained) include HepPar1 and glypican-3 positivity supporting hepatocellular origin; CD34 highlights sinusoidal capillarization in many HCCs; CK19 is typically negative or focally positive in certain variants; clinical correlation remains essential. Interpretation.

Imaging modality: Histopathology; Technique: Hematoxylin and Eosin (H&E) stained section with ancillary iron staining (Prussian blue) to identify hemosiderin. Specimen: Liver tissue, left hepatic lobe. The image demonstrates hepatocellular carcinoma (HCC) with a prominent acinar (pseudoglandular) growth pattern, forming gland-like spaces within malignant hepatocytes and separating from the adjacent native liver parenchyma. The tumor is well-demarcated from surrounding parenchyma, with a crisp interface and abrupt transition. The native liver shows marked hemosiderin deposition, consistent with long-standing hemochromatosis. Hemosiderin appears as brown granular pigment within hepatocytes and can be distinguished from bile by iron stains that yield positive results. The HCC cells are polygonal, with eosinophilic cytoplasm and variable nuclear atypia; architectural pattern includes acinar arrangements resembling glands rather than exclusively trabecular plates. Iron overload is clinically relevant as a widely recognized risk factor for hepatocarcinogenesis. Pathology findings support a diagnosis of iron-overload–associated hepatocellular carcinoma in a liver with iron deposition. Clinically, this morphology has implications for prognosis and therapeutic planning, including consideration of hepatic resection and post-operative surveillance. This image serves as a teaching resource illustrating iron overload, HCC histology, and the utility of iron staining in differentiating hemosiderin from bile.

Imaging modality: Histopathology; Technique: Hematoxylin and Eosin (H&E) stained section with ancillary iron staining (Prussian blue) to identify hemosiderin. Specimen: Liver tissue, left hepatic lobe. The image demonstrates hepatocellular carcinoma (HCC) with a prominent acinar (pseudoglandular) growth pattern, forming gland-like spaces within malignant hepatocytes and separating from the adjacent native liver parenchyma. The tumor is well-demarcated from surrounding parenchyma, with a crisp interface and abrupt transition. The native liver shows marked hemosiderin deposition, consistent with long-standing hemochromatosis. Hemosiderin appears as brown granular pigment within hepatocytes and can be distinguished from bile by iron stains that yield positive results. The HCC cells are polygonal, with eosinophilic cytoplasm and variable nuclear atypia; architectural pattern includes acinar arrangements resembling glands rather than exclusively trabecular plates. Iron overload is clinically relevant as a widely recognized risk factor for hepatocarcinogenesis. Pathology findings support a diagnosis of iron-overload–associated hepatocellular carcinoma in a liver with iron deposition. Clinically, this morphology has implications for prognosis and therapeutic planning, including consideration of hepatic resection and post-operative surveillance. This image serves as a teaching resource illustrating iron overload, HCC histology, and the utility of iron staining in differentiating hemosiderin from bile.

This diagnostic image series consists of three axial abdominal MRI scans (A, B, and C) illustrating a dynamic contrast-enhanced study of the liver. The focus is a focal liver lesion located in Segment VII, indicated by white arrows, identified as a combined hepatocellular-cholangiocarcinoma (cHCC-CCA). Panel A (Arterial Phase) demonstrates clear arterial phase hyperenhancement (APHE), where the lesion appears hyperintense relative to the surrounding parenchyma. Panel B (Portal Venous Phase) shows the lesion remaining relatively isointense or slightly hyperintense compared to the liver, notably lacking the classic 'washout' often seen in pure hepatocellular carcinoma. Panel C (Delayed/Late Phase) reveals progressive centripetal or gradual contrast enhancement within the lesion, a feature more characteristic of the cholangiocarcinoma component. This comparison chart is an educational tool for distinguishing between primary liver malignancies based on LI-RADS imaging criteria, specifically highlighting how atypical enhancement patterns can suggest a combined histology (cHCC-CCA) rather than isolated HCC.

This diagnostic image series consists of three axial abdominal MRI scans (A, B, and C) illustrating a dynamic contrast-enhanced study of the liver. The focus is a focal liver lesion located in Segment VII, indicated by white arrows, identified as a combined hepatocellular-cholangiocarcinoma (cHCC-CCA). Panel A (Arterial Phase) demonstrates clear arterial phase hyperenhancement (APHE), where the lesion appears hyperintense relative to the surrounding parenchyma. Panel B (Portal Venous Phase) shows the lesion remaining relatively isointense or slightly hyperintense compared to the liver, notably lacking the classic 'washout' often seen in pure hepatocellular carcinoma. Panel C (Delayed/Late Phase) reveals progressive centripetal or gradual contrast enhancement within the lesion, a feature more characteristic of the cholangiocarcinoma component. This comparison chart is an educational tool for distinguishing between primary liver malignancies based on LI-RADS imaging criteria, specifically highlighting how atypical enhancement patterns can suggest a combined histology (cHCC-CCA) rather than isolated HCC.

Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Now I have enough rich content for a comprehensive answer. Let me compile it.

Hepatocellular Carcinoma (HCC) - Full Details

Definition & Overview

Hepatocellular carcinoma (HCC) is the most common primary malignant tumor of the liver, arising from malignant transformation of hepatocytes. It is the third leading cause of cancer death worldwide, accounting for approximately 900,000 new cases and 830,000 deaths annually. More than 80% of cases occur in developing countries. Rates are rising in developed nations due to chronic hepatitis C, non-alcoholic steatohepatitis (NASH), and alcohol-related cirrhosis.
  • Goldman-Cecil Medicine, p. 2063

Epidemiology & Risk Factors

Risk FactorNotes
Hepatitis B virus (HBV)Can cause HCC without cirrhosis via direct viral DNA integration into host genome
Hepatitis C virus (HCV)Typically causes HCC after long-standing cirrhosis
Cirrhosis (any cause)Alcohol, NASH, hemochromatosis, primary biliary cirrhosis
AflatoxinDietary carcinogen (mold toxin); major factor in sub-Saharan Africa and Asia
NASH/NAFLDRising cause in Western countries
Alcohol-related liver diseaseVia cirrhosis
Hemochromatosis (iron overload)Direct hepatotoxic + carcinogenic effect
Geographic distribution closely parallels HBV and HCV prevalence. In Western countries, incidence is increasing as a direct consequence of the hepatitis C epidemic and the obesity/NASH epidemic.
  • Grainger & Allison's Diagnostic Radiology, p. 628
  • Current Surgical Therapy 14e, p. 418

Pathobiology & Molecular Mechanisms

HCC is an epithelial neoplasm arising from a multi-step carcinogenesis process triggered by chronic liver injury:
  1. Chronic inflammation, necrosis, and regeneration lead to progressive accumulation of somatic mutations
  2. Oncogene activation or tumor suppressor gene inactivation occurs over years
Key molecular alterations:
  • TERT promoter mutations - seen in ~45% of cases (activation of telomerase reverse transcriptase)
  • TP53 inactivation - seen in ~30% of cases
  • CTNNB1 (β-catenin) activation - seen in ~25% of cases
  • Additional alterations in Wnt signaling, cell cycle, and chromatin-remodeling pathways
HBV-specific mechanism: Direct viral DNA integration into the host genome at specific loci, particularly activating the TERT promoter, bypassing the usual cirrhosis-dependent pathway.
  • Goldman-Cecil Medicine, p. 2063 (Pathobiology section)

Morphological Patterns

  • Solitary (most common in non-cirrhotic settings)
  • Multifocal - in up to 40% of cases (particularly common in the Far East)
  • Diffuse (rare)
  • Fibrolamellar HCC (FL-HCC) - a distinct variant with thick lamellar bands of dense eosinophilic collagen separating broad cords of neoplastic hepatocytes; arises in younger patients and non-cirrhotic livers; distinct biology and often better prognosis than conventional HCC
Histologically, HCC shows trabecular, acinar (pseudoglandular), or solid growth patterns. Classic features include hepatocyte-like cells with abundant eosinophilic cytoplasm, prominent nucleoli, bile production, and absence of portal tracts within the tumor. HepPar-1 and glypican-3 are immunohistochemical markers supporting hepatocellular origin.

Clinical Manifestations

Asymptomatic: Commonly detected via surveillance imaging in at-risk patients (cirrhosis, chronic viral hepatitis).
Symptomatic presentations:
  • Right upper quadrant pain or a palpable mass
  • Nausea, early satiety (mass effect)
  • Weight loss, fevers, night sweats
  • Jaundice (from biliary obstruction)
  • Signs of portal hypertension
  • Hemorrhage from tumor rupture (especially in large lesions)
Paraneoplastic syndromes (rare):
  • Hypercalcemia of malignancy
  • Erythrocytosis (from erythropoietin production by tumor)
  • Hypoglycemia
Metastatic sites: Lung (most common), peritoneum, bone, spleen, adrenal gland, brain.
  • Goldman-Cecil Medicine, Clinical Manifestations section

Diagnosis

Tumor Markers

MarkerNotes
Alpha-fetoprotein (AFP)Primary marker; markedly elevated levels are diagnostic even without imaging confirmation. However, HCC can occur with a normal AFP
CA 19-9Add when diagnosis is unclear (to rule out cholangiocarcinoma)
CEAAdd when diagnosis is unclear

Imaging

Ultrasound (US):
  • Used as primary screening modality
  • Small HCCs may be hyper- or hypoechoic relative to surrounding parenchyma
  • Large lesions show internal heterogeneity (hemorrhage, necrosis, fat)
  • Portal vein tumor thrombus - pathognomonic of advanced HCC
  • High-velocity Doppler signals reflect arterioportal shunting
  • Limited sensitivity (60-80%) for lesions ≤1 cm in cirrhotic livers
CT (Multiphasic):
  • Unenhanced CT: ill-defined low-attenuation lesions; calcification in ~7.5%; fat accumulation possible
  • Classic pattern: Homogeneous arterial phase hyperenhancement (APHE) with portal venous/delayed phase washout - virtually diagnostic of HCC
  • "Mosaic" enhancement pattern seen in some lesions
  • Late arterial phase imaging is essential - many lesions visible only in this phase
MRI (gold standard for sensitivity):
  • Most sensitive technique for HCC detection
  • T1-weighted: typically decreased signal (some high T1 signal from glycogen accumulation)
  • T2-weighted: moderately increased signal with internal heterogeneity
  • Contrast enhancement pattern mirrors CT: arterial phase enhancement with washout
  • 5-10% of HCCs are atypical (relatively avascular)
  • Hepatobiliary-phase agents (Gd-EOB-DTPA) improve characterization

LI-RADS Classification

The Liver Imaging Reporting and Data System (LI-RADS) standardizes terminology for liver lesions in patients with chronic liver disease at risk for HCC:
LI-RADS CategoryMeaning
LR-1Definitely benign
LR-2Probably benign
LR-3Intermediate probability
LR-4Probably HCC
LR-5Definitely HCC (diagnostic)
LR-MProbably malignant, not HCC-specific
A LI-RADS 5 lesion is diagnostic of HCC - biopsy is not required in the appropriate clinical context.

Biopsy

Not indicated in the typical setting of chronic liver disease with classic imaging findings. May be needed for:
  • Atypical imaging characteristics
  • Molecular analysis to guide systemic therapy selection

Staging Systems

Three main staging systems are used in clinical practice:

1. AJCC/TNM Staging

Standard oncologic staging based on tumor size, vascular invasion, lymph node involvement, and metastasis.

2. Barcelona Clinic Liver Cancer (BCLC) Staging

Most widely used. Incorporates tumor burden, liver function, and performance status. Directly links stage to treatment strategy:
BCLC StageDescriptionRecommended Treatment
0 (Very early)Single tumor ≤2 cm, no vascular invasion, Child-Pugh AResection, ablation, transplant
A (Early)1-3 nodules ≤3 cm, Child-Pugh A-BResection, ablation, transplant
B (Intermediate)Multinodular, preserved liver functionTACE
C (Advanced)Vascular invasion or extrahepatic spreadSorafenib/lenvatinib ± immunotherapy
D (Terminal)Poor liver function (Child-Pugh C)Best supportive care

3. Okuda Staging

Older system incorporating tumor size, ascites, albumin, and bilirubin.

Child-Turcotte-Pugh Score (for liver function assessment)

Measure1 Point2 Points3 Points
Total bilirubin (mg/dL)<22-3>3
Serum albumin (g/L)>3528-35<28
PT/INR<1.71.71-2.30>2.30
AscitesNoneMildModerate to severe
Hepatic encephalopathyNoneGrades I-IIGrades III-IV
  • Class A: 5-6 points (well-compensated)
  • Class B: 7-9 points (significant compromise)
  • Class C: 10-15 points (decompensated)

Treatment

HCC management requires simultaneous management of the underlying chronic liver disease. Treatment is multidisciplinary.

1. Liver Transplantation (Preferred in cirrhotic patients)

  • Addresses both the malignancy AND the underlying liver disease
  • Eliminates the "field defect" (entire cirrhotic liver removed, preventing de novo HCC)
  • Milan Criteria for transplant eligibility: single tumor ≤5 cm, or up to 3 tumors each ≤3 cm, no vascular invasion, no extrahepatic disease
  • Limited by organ availability and immunosuppression risks
  • Best option for patients with advanced cirrhosis and limited HCC

2. Surgical Resection

  • Excellent option for limited liver disease and/or tumors beyond transplant criteria
  • Requires Child-Pugh A (and absence of portal hypertension) for major hepatectomy
  • Perioperative mortality <5% in Child-Pugh A; significantly higher in B or C
  • Preferred: anatomic resection (sectionectomy, segmentectomy) - HCC spreads along portal venous tributaries; associated with improved recurrence-free and overall survival
  • No proven adjuvant systemic therapy post-resection

3. Thermal Ablation

  • Excellent for local tumor control in non-surgical candidates
  • Radiofrequency ablation (RFA) or microwave ablation for tumors <2-3 cm
  • Randomized trials show long-term outcomes similar to surgical resection for small HCC, with less morbidity
  • Also used as bridge to transplantation

4. Intra-Arterial (Locoregional) Therapies

Used when curative options are not available; also used as bridge to transplantation:
  • TACE (Transarterial Chemoembolization) - standard of care for intermediate-stage (BCLC-B)
  • HAE (Hepatic Arterial Embolization, "bland")
  • TARE / SIRT (Transarterial Radioembolization with Yttrium-90) - for tumors 3-5 cm or portal vein thrombosis
  • Reserved when transplant, resection, or ablation are not feasible

5. Systemic Therapy (Advanced/Metastatic HCC - BCLC-C)

First-line options:
AgentClassNotes
Atezolizumab + BevacizumabPD-L1 inhibitor + anti-VEGFCurrent preferred first-line combination
SorafenibMultikinase inhibitor (anti-VEGFR, RAF)First approved systemic agent
LenvatinibMultikinase inhibitorNon-inferior to sorafenib in first-line
Durvalumab + TremelimumabAnti-PD-L1 + anti-CTLA-4Approved first-line option
Second-line options:
AgentClass
RegorafenibMultikinase inhibitor
CabozantinibMultikinase inhibitor (anti-MET, VEGFR)
RamucirumabAnti-VEGFR-2 (AFP ≥400 ng/mL)
Nivolumab ± ipilimumabAnti-PD-1 ± anti-CTLA-4
PembrolizumabAnti-PD-1
  • Current Surgical Therapy 14e, p. 418; Goldman-Cecil Medicine (Abstract section)

Surveillance

In high-risk patients (cirrhosis, chronic HBV, chronic HCV with advanced fibrosis):
  • Abdominal ultrasound every 6 months ± AFP
  • Recommended by AASLD and EASL guidelines
  • MRI preferred for surveillance in patients with poor ultrasound windows (obesity, NASH)

Prognosis

  • Overall 5-year survival <30% for all comers
  • Early-stage (BCLC 0-A) treated with curative intent: 5-year survival 50-75%
  • Advanced-stage (BCLC-C) with systemic therapy: median overall survival ~13-19 months (improved with immunotherapy combinations)
  • Portal vein tumor thrombus, extrahepatic metastasis, and poor liver function are major adverse prognostic factors

Key Images

HCC Histology - Solid Pattern (H&E):
HCC solid growth pattern H&E histology
Solid sheets of monomorphic hepatocyte-like cells with abundant eosinophilic cytoplasm, prominent nucleoli, and intracellular bile. Portal tracts are absent - characteristic of HCC.
Fibrolamellar HCC (H&E):
Fibrolamellar HCC histology with lamellar fibrous stroma
Thick lamellar bands of dense eosinophilic collagen separating large polygonal tumor cells with granular cytoplasm - the hallmark of fibrolamellar HCC, arising in younger patients without cirrhosis.
MRI - Combined HCC/Cholangiocarcinoma showing arterial hyperenhancement:
MRI dynamic contrast liver HCC arterial hyperenhancement LI-RADS
Axial MRI: Panel A (arterial phase) shows APHE; Panel B (portal venous phase) lacks classic washout; Panel C (delayed) shows progressive enhancement - illustrating how atypical enhancement raises suspicion for combined HCC-cholangiocarcinoma.

Recent Evidence (2024-2026)

A 2024 systematic review of clinical practice guidelines for HCC management found that guidelines consistently recommend surveillance ultrasound ± AFP, LI-RADS for imaging characterization, BCLC staging for treatment allocation, and the atezolizumab-bevacizumab combination as preferred first-line systemic therapy for advanced HCC. A 2025 systematic review on molecular targeting highlights the shift toward combined immunotherapy plus anti-angiogenic regimens and the role of biomarker-driven treatment selection in HCC.

Summary Table
FeatureKey Point
Most common primary liver cancerYes - 900,000 cases/year globally
Primary risk factorsHBV, HCV, cirrhosis (any cause), aflatoxin, NAFLD/NASH
Classic imagingArterial hyperenhancement + portal venous washout
Diagnostic imaging classificationLI-RADS (LR-5 = diagnostic)
Curative optionsTransplant, resection, ablation
Bridge/palliative locoregionalTACE, TARE (Y-90)
First-line systemicAtezolizumab + bevacizumab (preferred); sorafenib; lenvatinib
Key molecular alterationsTERT (45%), TP53 (30%), CTNNB1 (25%)
SurveillanceUS ± AFP every 6 months in at-risk patients
Prognosis (overall 5-year)<30%
This is a shared conversation. Sign in to Orris to start your own chat.